Well-known pharmaceutical companies filed for bankruptcy Many pharmaceutical companies have sold their assets.

Pharmaceutical Network October 15 - Well-known pharmaceutical industry filed for bankruptcy October 13, Haizheng Pharmaceuticals issued "on the holding subsidiary Yunnan Biopharmaceutical Co., Ltd. filed for bankruptcy restructuring progress announcement."
the announcement, the Kunming Intermediate People's Court of Yunnan Province has decided to initiate pre-re-restructuring of Yunsheng Company in accordance with its application.
It is understood that since 2016, Yunnan Biopharmaceuticals has been affected by internal and external factors, business performance has continued to decline, product planning and project construction has stagnated, and has become insolvent, there is a risk of unable to pay off maturing debts, which in turn affects the continued operating capacity of Haizheng Pharmaceuticals.
As of the first half of this year, Haizheng Pharmaceuticals and its subsidiaries had received 121 million yuan in receivables from Yunsheng, 18.68 million yuan in bad debts, 150 million yuan in long-term equity investment in Yunsheng, 150 million yuan in impairments on long-term equity investments, and 92.6 million yuan in goodwill recognized by Yunsheng at the consolidated level.
said the bankruptcy and restructuring of Yunnan Biopharmaceuticals will not affect the company's existing main business production and operation.
public information shows that Haizheng Pharmaceuticals' financial position has declined since 2015, with its first loss since its listing in 2016 and a loss of 492 million yuan in 2018.
2019, the company through the sale of houses, peacocks and other measures to in-live assets, to achieve a profit of 930.727 million yuan.
believe that selling assets is a shortcut for companies to make their performance better.
, especially under the influence of this year's new crown outbreak, many pharmaceutical companies are counting on this approach to maintain performance.
8 listings are still hard to find sellers October 14, Lemie pharmaceutical company issued a notice, disclosing the company's public listing of the transfer of four subsidiaries progress.
announcement, as of October 12, 2020, the public listing of the underlying shares expires, the current round of listing transfer has not been solicited to the intention of the transferor.
, after eight listings, it is still difficult to find a buyer for lems Pharmaceuticals' transfer of its stake in the subsidiary.
Laimei Pharmaceuticals said in its previously released 2020 half-yearly report that the listing is to avoid the Company and its subsidiaries to create industry competition, focusing core resources around the company's strategic development plan, to the possible problems of competition in the industry and does not meet the future strategic planning of the subsidiary equity disposal.
company will actively take a variety of ways to dispose of related assets according to the actual situation, including but not limited to public listing transfer, the introduction of strategic investors, the sale of some assets, etc., in order to further optimize the company's asset structure.
failed to make several transfers, hitting the industry with big questions about the deal's eventual success.
but there is no doubt that Lemite Pharmaceuticals is very determined to optimize the company's asset structure, accelerate capital withdrawals, and focus on the development of core areas.
many pharmaceutical companies have sold their assets this year, the sale of subsidiaries, equity, real estate listed pharmaceutical companies reached more than 10, many pharmaceutical companies have been in the assets to reduce debt.
For example, Kazakhstan Pharmaceuticals Co., Ltd. recently announced that its subsidiary Ha Pharmaceutical Group Pharmaceutical Co., Ltd. intends to sell the property at 1288 1 Xikang Road, Shanghai, to a natural person for 13.1 million yuan, a move aimed at insulate assets, improve asset operating efficiency and increase the company's liquidity.
pharmaceutical shares said that the proposed disposal of the property is the company's non-core assets, the company is expected to increase the current profit and loss of 7 million to 10 million yuan.
In addition, Haizheng Pharmaceuticals, which has repeatedly sold properties, issued an announcement and signed a transfer contract with Shanghai Xinyuan Industrial Co., Ltd. to transfer six four-story factories at 471 Guiping Road, Xuhui District, Shanghai, to the latter, with a transaction value of 15.15 million yuan.
's move is also to in-live the company's idle assets, improve the efficiency of the company's assets.
the transaction confirms that the net profit attributable to the owner of the parent company is approximately RMB10.5 million.
recent announcement of Guoxin Health Disclosure also shows that in order to focus on the company's main business and further optimize the company's financial structure, the company intends to transfer 45% of Guangdong Haihong's shares through public listing.
the transfer floor price of the public listing is not less than 137.7 million yuan.
the proposed sale of Guangdong Haihong business scope includes drugs, medical equipment bidding agents and computer software development.
the first half of this year, 195 of the 345 A-share listed biopharmaceutical companies reported year-on-year revenue declines, accounting for more than half of the total, and 167 companies reported year-on-year declines in net profit.
behind frequent asset sales or under pressure to operate.
when performance continues to decline, some listed companies tend to adjust the business structure by selling assets, inventory assets, so as to obtain a certain amount of income.
but this benefit model is one-off and not sustainable, and the company still needs to be transformed and upgraded to address the issue if it is to achieve follow-up growth.
.